Abstract
Background: While immune checkpoint inhibitors have transformed cancer therapy, their efficacy in gliomas remains limited. This study aims to identify gene expression signatures related to glioma prognosis and construct a predictive model for patient survival. Methods: Calcium-related differentially expressed genes (DEGs) were analyzed across two independent databases (TCGA and Wang et al.). An 18-gene prognostic signature was developed using Cox regression and validated across multiple cohorts. The relationship between this signature and the tumor microenvironment (TME) was evaluated using the CIBERSORT algorithm. Results: A 415-gene intersection of DEGs was identified, with the calcium signaling pathway being significantly enriched. A risk score derived from the 18-gene signature effectively stratified patients into high- and low-risk groups. High-risk scores correlated with worse outcomes, characteristic clinical features (e.g., IDH-wildtype), and markers of T-cell exhaustion (PD-1, LAG3, TIM-3). Conclusion: Calcium signaling is deeply linked to immunosuppression in gliomas. Targeting this pathway may offer a new strategy to improve immunotherapy efficacy.
Introduction
Gliomas are the most common and aggressive primary brain tumors, characterized by high morbidity and poor prognosis. Despite standard treatments including surgery and chemo-radiotherapy, survival rates remain low. Immunotherapy, particularly immune checkpoint blockade, has failed to achieve significant breakthroughs in gliomas due to the highly immunosuppressive "cold" tumor microenvironment (TME). Identifying the genetic drivers of this immunosuppression is critical for developing better prognostic tools and therapeutic strategies.
Identification of Calcium-Related Prognostic Genes
To uncover the molecular basis of glioma progression, researchers performed a comprehensive bioinformatics analysis of large-scale datasets. By comparing glioma tissues with normal brain tissues in the TCGA and Wang et al. cohorts, they identified a core set of 415 differentially expressed genes (DEGs).
Functional enrichment analysis revealed that these genes were most significantly involved in the calcium signaling pathway. Calcium ions are vital secondary messengers that regulate diverse cellular processes, including proliferation and immune response. From this pool, an 18-gene panel was selected using Univariate and Multivariate Cox regression to construct a prognostic risk score.
The Calcium-Immune Axis and the Tumor Microenvironment
A central finding of this study is the profound connection between disrupted calcium signaling and the immune landscape of gliomas. The researchers discovered that low expression of the 18 calcium-related genes (resulting in a high-risk score) was strongly associated with an immunosuppressive environment.
Key observations included:
- T-cell Exhaustion: High-risk scores significantly correlated with increased expression of exhausted T-cell markers, such as PD-1, LAG3, and TIM-3. This suggests that while immune cells may be present in the tumor, they are functionally inactive.
- Macrophage Polarization: High-risk tumors were heavily infiltrated by M2 macrophages, which promote tumor growth and suppress anti-tumor immunity, rather than the tumor-attacking M1 phenotype.
- Immunosuppressive Signaling: The data indicates that the calcium signaling pathway plays a regulatory role in maintaining the "cold" TME that allows gliomas to evade the immune system.
Clinical Utility and Prognostic Power
The 18-gene risk score proved to be a robust independent prognostic factor. In validation cohorts, the model achieved high predictive accuracy, with an Area Under the Curve (AUC) of 0.791 at two years. Patients in the low-risk group had significantly longer overall survival compared to those in the high-risk group across all datasets (p < 0.001).
To translate these findings into clinical practice, the authors developed a nomogram that integrates the risk score with traditional clinical markers like age and IDH mutation status. This tool achieved a C-index of 0.743, providing clinicians with a reliable method for predicting 1-, 2-, and 3-year survival probabilities.
Conclusion
This study establishes the calcium signaling pathway as a critical regulator of the glioma immune microenvironment and a powerful predictor of patient prognosis. The identified 18-gene signature not only offers a new tool for risk stratification but also highlights calcium signaling as a potential therapeutic target. Reversing the calcium-mediated immunosuppression could be the key to "thawing" the cold microenvironment of gliomas and improving the success of immunotherapy.
Summary updated